EAOO launches first strategic plan

Article

The European Academy of Optometry and Optics (EAOO) has launched its first 3-year strategic plan for 2014 through 2016.

The European Academy of Optometry and Optics (EAOO) has launched its first 3-year strategic plan for 2014 through 2016. The Academy was originally launched in 2009, with plans to strengthen and develop its growing network of eye and vision care professionals across Europe in order to raise the standards and practice of optometry and optics.

Clinical practice, education and research development will be the three areas of focus for the Academy over the next 3 years, with the following objectives:

  • Clinical practice: to promote good clinical practice by members of the Academy and support their scope of practice.
  • Education: to promote excellence in optometric and optical education at the university and college level through the sharing of skills, knowledge and experience between professors, academic staff and students.
  • Research development: to encourage innovation in the development and application of research in optometry, optics and vision science in Europe.

Other objectives include communicating effectively with members, working towards financial sustainability and strengthening relationships with the European Council of Optometry and Optics (ECOO) and other strategic partners.

Paul Murphy, president of the EAOO, said: "It's nearly five years since the Academy was founded, and while a lot has been achieved, we are excited to be starting out on a new path that will bring further benefits to Academy members, and improvements to vision care across Europe. I'm delighted that the Academy has agreed its new 3-year strategic plan, which will guide us as we continue to expand our work."

To access the strategic plan, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.